Drug Comparisons
Understand how retatrutide compares to other medications in the incretin and metabolic therapy space. Our comparisons examine mechanism of action, receptor activity, clinical efficacy, side-effect profiles, and development status using published evidence.
Featured Comparisons
Retatrutide vs Bariatric Surgery: Can a Triple Agonist Match Surgical Weight Loss?
Comparing retatrutide's clinical trial weight loss results to bariatric surgery outcomes — gastric bypass, sleeve gastrectomy, and adjustable gastric banding. A detailed look at efficacy, risks, reversibility, and who might benefit from each approach.
Retatrutide vs CagriSema: Next-Generation Obesity Drugs Compared
Retatrutide vs CagriSema compared: Phase 3 weight loss data, mechanism differences (triple agonist vs amylin/GLP-1), liver fat, side effects, and expected availability for these next-generation obesity treatments.
Retatrutide vs Zepbound: Which Eli Lilly Drug Produces More Weight Loss?
Head-to-head comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) and Zepbound (tirzepatide, dual GIP/GLP-1 agonist) for obesity and weight loss, featuring Phase 3 TRIUMPH-4 data showing -28.7% weight loss vs Zepbound's -22.5% in SURMOUNT-1.
Retatrutide vs Wegovy: Weight Loss Comparison, Side Effects & Differences
Retatrutide vs Wegovy compared: TRIUMPH-4 Phase 3 results (-28.7% weight loss), side effect profiles, mechanism of action, liver fat data, and when retatrutide may be available.
Retatrutide vs Ozempic: How the Triple Agonist Compares to Semaglutide
An evidence-based comparison of retatrutide and Ozempic (semaglutide 1mg) — covering weight loss results, side effects, mechanism differences, and current availability. Updated March 2026.
Retatrutide vs Tirzepatide: Weight Loss Results, Mechanism & Key Differences
Compare retatrutide and tirzepatide head-to-head: TRIUMPH-4 Phase 3 weight loss data (-28.7%), mechanism differences, side effects, liver fat reduction, and when each drug may be available.
Retatrutide vs Semaglutide: Triple Agonist vs GLP-1 Compared
How does retatrutide compare to semaglutide? TRIUMPH-4 Phase 3 data (-28.7% weight loss), mechanism differences, side effects, liver fat reduction, and development status compared.
All Comparisons
Retatrutide vs Liraglutide (Saxenda): A Comparison
How retatrutide's triple agonist mechanism compares to liraglutide (Saxenda) — efficacy, dosing, safety, and availability.
Retatrutide vs Phentermine: Old Guard Meets New
How retatrutide compares to phentermine — the most prescribed weight loss drug in America — on efficacy, safety, cost, and mechanism.
Retatrutide vs Orforglipron (Foundayo): Triple Agonist vs Oral GLP-1
Comparing retatrutide (investigational triple agonist) and orforglipron (Foundayo, FDA-approved oral GLP-1), both from Eli Lilly.
Retatrutide vs Mounjaro: Triple Agonist vs Dual Agonist for Diabetes
Comprehensive comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) and Mounjaro (tirzepatide, dual GIP/GLP-1 agonist) for type 2 diabetes, including Phase 3 TRIUMPH-4 data showing -28.7% weight loss, glycemic control, liver fat reduction, and safety profiles.
Retatrutide vs Survodutide: Comparing Two Glucagon-Containing Agonists
In-depth comparison of retatrutide (triple GIP/GLP-1/glucagon agonist by Eli Lilly) and survodutide (dual GLP-1/glucagon agonist by Boehringer Ingelheim), including Phase 3 TRIUMPH-4 data, the role of GIP receptor agonism, MASLD/MASH positioning, and clinical development timelines.